fluconazole has been researched along with Neutropenia in 202 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cefpirome was administered as prophylaxis against bacterial infection, and meropenem+minocycline as an empiric window therapy for febrile neutropenia." | 9.14 | [Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation]. ( Higuchi, B; Hirano, S; Inoue, M; Ishihara, T; Kawa, K; Kondo, O; Kouroki, M; Koyama, M; Sakata, A; Sakata, N; Sawada, A; Takeshita, Y; Yasui, M; Yoshioka, A, 2009) |
| "5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i." | 9.12 | An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006) |
| " We performed a randomized trial to compare itraconazole vs fluconazole, for prevention of IFIs in patients with acute leukemia (AL) and HSCT recipients." | 9.12 | A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. ( Akria, L; Benyamini, N; Dally, N; Dann, EJ; Fineman, R; Gorelik, A; Haddad, N; Oren, I; Rowe, JM; Sprecher, H; Tamir, A; Zuckerman, T, 2006) |
| "In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival." | 9.12 | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007) |
| " The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever." | 9.11 | Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004) |
| "We hypothesized that chemoprophylaxis with the echinocandin micafungin would be an effective agent for antifungal prophylaxis during neutropenia in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 9.11 | Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. ( Bunin, N; Hiemenz, JW; Lee, JM; Lipton, JH; Miller, CB; Ratanatharathorn, V; Satoi, Y; Stepan, DE; van Burik, JA; Vesole, DH; Wall, DA; Walsh, TJ, 2004) |
| "A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study." | 9.08 | Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995) |
| "We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0." | 9.08 | A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998) |
| "In patients without neutropenia and without major immunodeficiency, fluconazole and amphotericin B are not significantly different in their effectiveness in treating candidemia." | 9.07 | A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. ( Bennett, JE; Dine, AP; Edwards, JE; Karchmer, AW; Pappas, PG; Rex, JH; Scheld, WM; Sugar, AM; van der Horst, CM; Washburn, RG, 1994) |
| "To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia." | 9.07 | Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. ( Barbui, T; Bucaneve, G; Carotenuto, M; D'Antonio, D; Del Favero, A; Fasola, G; Liso, V; Mandelli, F; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Ricci, P, 1994) |
| "An open, randomized study was performed at 18 European centres to compare the efficacy, safety and tolerance of oral fluconazole with oral polyenes for the prophylaxis of fungal colonization and infection in adults at high risk of developing neutropenia." | 9.07 | Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. ( Brammer, KW; Ehninger, G; Mufti, GJ; Philpott-Howard, JN; Wade, JJ, 1993) |
| "Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated." | 9.07 | Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. ( Buell, DN; Chandrasekar, PH; Goodman, JL; Ho, WG; Horowitz, H; Islam, MZ; Lazarus, HM; Rosenfeld, CS; Shadduck, RK; Silber, JL; Winston, DJ, 1993) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 8.90 | Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 8.83 | Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006) |
| "Fluconazole is compared with other agents for antifungal prophylaxis in patients with chemotherapy-induced neutropenia." | 8.79 | Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. ( Briceland, LL; Preston, SL, 1995) |
| "Systemic Candida infections are a major cause of infectious morbidity and mortality during chemotherapy-induced neutropenia." | 7.77 | The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. ( Wingard, JR, 1992) |
| "In this study, we investigated the in vivo efficacy of anidulafungin during the early phase of disseminated candidiasis in a neutropenic murine model and compared the results with those obtained for fluconazole." | 7.76 | Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. ( Chandrasekar, PH; Cutright, JL; Krishnan-Natesan, S; Manavathu, EK, 2010) |
| "A cost-effectiveness analysis was performed to investigate the financial impact of using posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia." | 7.74 | Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. ( Collins, CD; Ellis, JJ; Kaul, DR, 2008) |
| " We performed 24-h pharmacodynamic studies to compare the efficacies of anidulafungin, fluconazole, and amphotericin B in neutropenic mice with disseminated candidiasis caused by one of three strains of Candida glabrata." | 7.73 | Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. ( Deziel, MR; Drusano, GL; Drusano, MF; Gumbo, T; Liu, W; Louie, A; Ma, L, 2006) |
| "Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia." | 7.73 | Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006) |
| "Due to an increasing number of leukemic patients with invasive gingival aspergillosis during neutropenia (neutrophils <500 cells/microl for >10 days), we evaluated the efficacy of oral itraconazole prophylaxis for preventing this invasive infection at our hospital." | 7.71 | Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. ( Fujihara, M; Kyo, T; Mikami, Y; Myoken, Y; Sugata, T, 2002) |
| "We determined the pharmacodynamic parameter and the magnitude of that parameter that was predictive of the efficacy of fluconazole in the treatment of disseminated candidiasis." | 7.70 | Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. ( Andes, D; van Ogtrop, M, 1999) |
| "The efficacy and safety of fluconazole, a new triazole antifungal agent, was evaluated in 24 patients with neutropenia due to cytotoxic anticancer chemotherapy with polyfactorial immunodepression." | 7.68 | Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients. ( Blahova, M; Fuchsberger, P; Hornikova, M; Koza, I; Krcméry, V; Mardiak, J; Migom, C; Savko, V; Spanik, S; Sufliarsky, J, 1991) |
| "Disseminated candidiasis is a serious infectious complication with a mortality as high as 50%." | 6.68 | An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. ( de Pauw, BE; Donnelly, JP; Kullberg, BJ; Meis, JF; Raemaekers, JM, 1995) |
| "Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group)." | 5.36 | Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. ( Deremer, D; Dobbins, R; Eisa, N; El-Geneidy, M; Hall, P; Jillella, A; Lewis, G; Ustun, C, 2010) |
| "In vivo studies have described the pharmacodynamic (PD) characteristics of several triazoles." | 5.32 | In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. ( Andes, D; Conklin, R; Marchillo, K; Stamstad, T, 2003) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 5.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| "To compare the efficacy of caspofungin vs fluconazole prophylaxis against proven or probable invasive fungal disease and invasive aspergillosis during neutropenia following acute myeloid leukemia chemotherapy." | 5.30 | Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. ( Alexander, S; Callahan, C; Chen, L; Dang, H; Dvorak, CC; Esbenshade, AJ; Fisher, BT; Nieder, M; Sung, L; Villaluna, D; Wiley, JM; Wingard, JR; Zaoutis, T; Zerr, D, 2019) |
| "Treatment with fluconazole alone also significantly lowered the number of C." | 5.28 | Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. ( Kullberg, BJ; Poell, RJ; van 't Wout, JW; van Furth, R, 1992) |
| " Cefpirome was administered as prophylaxis against bacterial infection, and meropenem+minocycline as an empiric window therapy for febrile neutropenia." | 5.14 | [Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation]. ( Higuchi, B; Hirano, S; Inoue, M; Ishihara, T; Kawa, K; Kondo, O; Kouroki, M; Koyama, M; Sakata, A; Sakata, N; Sawada, A; Takeshita, Y; Yasui, M; Yoshioka, A, 2009) |
| "The objective of this study was to assess the costs and effectiveness (avoided invasive fungal infections - IFIs; overall mortality) of prophylaxis with posaconazole 200 mg per os TID and standard azoles (fluconazole 400 mg per os OD, itraconazole 200 mg per os BID) in neutropenic patients with acute myelogenous leukaemia or myelodysplastic syndromes." | 5.14 | [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome]. ( Lazzaro, C, 2010) |
| "5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i." | 5.12 | An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006) |
| " We performed a randomized trial to compare itraconazole vs fluconazole, for prevention of IFIs in patients with acute leukemia (AL) and HSCT recipients." | 5.12 | A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. ( Akria, L; Benyamini, N; Dally, N; Dann, EJ; Fineman, R; Gorelik, A; Haddad, N; Oren, I; Rowe, JM; Sprecher, H; Tamir, A; Zuckerman, T, 2006) |
| "In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival." | 5.12 | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007) |
| " The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever." | 5.11 | Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004) |
| "We hypothesized that chemoprophylaxis with the echinocandin micafungin would be an effective agent for antifungal prophylaxis during neutropenia in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 5.11 | Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. ( Bunin, N; Hiemenz, JW; Lee, JM; Lipton, JH; Miller, CB; Ratanatharathorn, V; Satoi, Y; Stepan, DE; van Burik, JA; Vesole, DH; Wall, DA; Walsh, TJ, 2004) |
| "A total of 317 neutropenic patients (<500 cells/mm3) with persistent or recrudescent fever despite 4 or more days of antibacterial therapy were randomly assigned to receive either fluconazole (400 mg intravenously once daily) or amphotericin B (0." | 5.09 | A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. ( Hathorn, JW; Schiller, GJ; Schuster, MG; Territo, MC; Winston, DJ, 2000) |
| "A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study." | 5.08 | Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995) |
| "We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0." | 5.08 | A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998) |
| " The association between Candida multicolonization and the occurrence of Candida infection seems to be confirmed by a double-blind placebo-controlled study performed in a small subgroup of the multicolonized patients treated with fluconazole." | 5.07 | Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. ( Boccanera, M; Cassone, A; De Bernardis, F; Girmenia, C; Martino, P; Micozzi, A, 1994) |
| "In patients without neutropenia and without major immunodeficiency, fluconazole and amphotericin B are not significantly different in their effectiveness in treating candidemia." | 5.07 | A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. ( Bennett, JE; Dine, AP; Edwards, JE; Karchmer, AW; Pappas, PG; Rex, JH; Scheld, WM; Sugar, AM; van der Horst, CM; Washburn, RG, 1994) |
| "The efficacy and safety of oral fluconazole versus a polyene regimen in preventing mycoses in neutropenic patients was compared." | 5.07 | Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. ( Burnie, J; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Hussain Qadri, SM; Kalin, M; Padmos, A; Spence, D, 1994) |
| "To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia." | 5.07 | Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. ( Barbui, T; Bucaneve, G; Carotenuto, M; D'Antonio, D; Del Favero, A; Fasola, G; Liso, V; Mandelli, F; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Ricci, P, 1994) |
| "An open, randomized study was performed at 18 European centres to compare the efficacy, safety and tolerance of oral fluconazole with oral polyenes for the prophylaxis of fungal colonization and infection in adults at high risk of developing neutropenia." | 5.07 | Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. ( Brammer, KW; Ehninger, G; Mufti, GJ; Philpott-Howard, JN; Wade, JJ, 1993) |
| "Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated." | 5.07 | Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. ( Buell, DN; Chandrasekar, PH; Goodman, JL; Ho, WG; Horowitz, H; Islam, MZ; Lazarus, HM; Rosenfeld, CS; Shadduck, RK; Silber, JL; Winston, DJ, 1993) |
| "Forty patients with acute leukemia (age 16-71 years, 13 females, 27 males) with induced neutropenia due to chemotherapy received either 50 mg fluconazole or 800 mg amphotericin B per day orally as prophylaxis against fungal infection." | 5.06 | [Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents]. ( Finke, R, 1990) |
| " Our study was designed to assess the prevention of (1) staphylococcal and streptococcal infections using T when the central catheter is being placed, and (2) candida infection by the simultaneous use of a new anti-mycotic agent fluconazole (F) administered once-daily." | 5.06 | Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children. ( Arlet, G; Baruchel, A; Schaison, G, 1990) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 4.90 | Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014) |
| "To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia." | 4.90 | Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gøtzsche, PC; Johansen, HK, 2014) |
| " Although fluconazole use has been considered one of the main causes for the epidemiologic change in invasive candidiasis, especially in the increase of species less sensitive to this agent, this association remains unproven." | 4.84 | [Current treatment of candidemia. Role of anidulafungin]. ( Almirante, B; Pemán, J, 2008) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 4.83 | Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006) |
| " Fluconazole (Diflucan) is currently the standard prophylactic agent for candidiasis, although mold-active agents and alternative strategies for polyene administration are being investigated." | 4.81 | Antifungal prophylaxis in hematopoietic stem cell transplant recipients. ( Marr, KA, 2001) |
| "To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia." | 4.81 | Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gøtzsche, PC; Johansen, HK, 2002) |
| "To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia." | 4.80 | Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gotzsche, PC; Johansen, HK, 2000) |
| "Fluconazole is compared with other agents for antifungal prophylaxis in patients with chemotherapy-induced neutropenia." | 4.79 | Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. ( Briceland, LL; Preston, SL, 1995) |
| " A second opinion at our institute resulted in the diagnosis of hepatic candidiasis without prior documented candidemia, for which she was treated successfully with fluconazole." | 3.85 | Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis? ( Bomers, MK; de Rooij, ML; Meijer, E; Menke-van der Houven van Oordt, CW; van Dijk, K; van Prehn, J, 2017) |
| "In patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), posaconazole has been proven more effective in the prevention of invasive fungal infection (IFI) than fluconazole or itraconazole (standard azoles) The current analysis seeks to estimate the cost effectiveness of prophylactic posaconazole compared with standard azoles in AML or MDS patients with severe chemotherapy-induced neutropenia in Sweden." | 3.80 | Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden. ( Åkerborg, Ö; Björkholm, M; Höglund, M; Lundberg, J, 2014) |
| " Patients receiving low-dose fluconazole prior to the positive BCx with a known indication for prophylaxis including neutropenia, ICU exposure or history of organ transplantation were classified as prophylaxis." | 3.80 | Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study. ( Chaudhari, P; Emons, MF; Khandelwal, N; Shorr, AF; Yu, HT; Zilberberg, M, 2014) |
| "Systemic Candida infections are a major cause of infectious morbidity and mortality during chemotherapy-induced neutropenia." | 3.77 | The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. ( Wingard, JR, 1992) |
| "In this study, we investigated the in vivo efficacy of anidulafungin during the early phase of disseminated candidiasis in a neutropenic murine model and compared the results with those obtained for fluconazole." | 3.76 | Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. ( Chandrasekar, PH; Cutright, JL; Krishnan-Natesan, S; Manavathu, EK, 2010) |
| "A cost-effectiveness analysis was performed to investigate the financial impact of using posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia." | 3.74 | Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. ( Collins, CD; Ellis, JJ; Kaul, DR, 2008) |
| ", with that of amphotericin B and fluconazole in a temporarily immunocompromised murine model of disseminated candidiasis." | 3.73 | Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. ( Denning, DW; Morrissey, G; Sharp, A; Warn, PA, 2005) |
| " We performed 24-h pharmacodynamic studies to compare the efficacies of anidulafungin, fluconazole, and amphotericin B in neutropenic mice with disseminated candidiasis caused by one of three strains of Candida glabrata." | 3.73 | Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. ( Deziel, MR; Drusano, GL; Drusano, MF; Gumbo, T; Liu, W; Louie, A; Ma, L, 2006) |
| "Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia." | 3.73 | Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006) |
| "A 22-yr-old male with acute lymphoblastic leukemia and Candida krusei fungemia failed therapy with fluconazole and amphotericin B." | 3.72 | Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent. ( McGee, WT; Tereso, GJ, 2003) |
| " We encountered a tuboovarian abscess caused by Candida glabrata after chemotherapy with an anticancer drug, methotrexate, in a febrile neutropenic patient." | 3.72 | Tuboovarian abscess caused by Candida glabrata in a febrile neutropenic patient. ( Mikamo, H; Ninomiya, M; Tamaya, T, 2003) |
| "Due to an increasing number of leukemic patients with invasive gingival aspergillosis during neutropenia (neutrophils <500 cells/microl for >10 days), we evaluated the efficacy of oral itraconazole prophylaxis for preventing this invasive infection at our hospital." | 3.71 | Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. ( Fujihara, M; Kyo, T; Mikami, Y; Myoken, Y; Sugata, T, 2002) |
| "We determined the pharmacodynamic parameter and the magnitude of that parameter that was predictive of the efficacy of fluconazole in the treatment of disseminated candidiasis." | 3.70 | Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. ( Andes, D; van Ogtrop, M, 1999) |
| " We describe the unanticipated problems we encountered in collecting data for a meta-analysis comparing a new antifungal agent, fluconazole, with amphotericin B in patients with cancer complicated by neutropenia." | 3.70 | Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. ( Gotzsche, PC; Johansen, HK, 1999) |
| "Candida krusei is inherently resistant to fluconazole and is emerging as a frequent cause of fungemia in patients with hematologic malignant neoplasms." | 3.70 | Candida krusei fungemia. An escalating serious infection in immunocompromised patients. ( Abbas, J; Abi-Said, D; Bodey, GP; Girgawy, E; Hachem, R; Hanna, HA; Mardani, M; Raad, I; Whimbey, E, 2000) |
| "The efficacy and safety of fluconazole, a new triazole antifungal agent, was evaluated in 24 patients with neutropenia due to cytotoxic anticancer chemotherapy with polyfactorial immunodepression." | 3.68 | Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients. ( Blahova, M; Fuchsberger, P; Hornikova, M; Koza, I; Krcméry, V; Mardiak, J; Migom, C; Savko, V; Spanik, S; Sufliarsky, J, 1991) |
| "We compared the efficacies of the new triazole antifungal drugs fluconazole and itraconazole with that of amphotericin B in vitro and in an animal model of systemic candidiasis in normal and neutropenic mice." | 3.67 | Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. ( Mattie, H; van Furth, R; Van t Wout, JW, 1989) |
| "Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients." | 2.73 | Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. ( Asakura, S; Fujii, N; Hara, M; Hiramatsu, Y; Ikeda, K; Maeda, Y; Matsuo, K; Matsuoka, KI; Miyata, A; Nawa, Y; Saito, T; Shinagawa, K; Sunami, K; Tabayashi, T; Tanimoto, M; Yano, T, 2008) |
| "Both cancer centers differed in prophylactic antibiotic policies." | 2.69 | Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. ( Foltinova, A; Kaiserova, E; Kiskova, M; Kovacicova, G; Krchnakova, A; Krcmery, V; Krupova, I; Kunova, A; Trupl, J; West, D, 1998) |
| "In neutropenic patients with hematologic malignancies, prophylaxis with fluconazole significantly decreased fungal isolation and other indicators of fungal infection when compared with amphotericin B." | 2.69 | Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. ( Fujimori, Y; Kakishita, E; Kanamaru, A; Okada, M; Okamoto, T; Takatsuka, H; Takemoto, Y; Tamura, S; Wada, H, 1999) |
| "Fluconazole was discontinued when a neutrophil count above 1." | 2.69 | Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. ( Goranov, S; Grudeva-Popova, J; Spasov, E; Vakrilov, V, 1999) |
| "Amphotericin B was significantly more toxic than Fluconazole especially in related allogeneic transplantation where 19% of patients developed toxicity vs 0% of Fluconazole recipients (p < 0." | 2.69 | Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. ( Bolwell, B; Collins, R; Dummer, S; Ericson, S; Fay, J; Freytes, CO; Goodman, SA; Greer, J; Herzig, RH; LeMaistre, F; Lynch, J; Pineiro, L; Pohlman, B; Stein, R; Stevens, D; Wolff, SN, 2000) |
| "Fluconazole prophylaxis was given to 12 patients for a mean of 21." | 2.69 | Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. ( Huijgens, PC; Simoons-Smit, AM; Timmers, GJ; Touw, D; van Loenen, AC; Zweegman, S, 2000) |
| "Fungal infections are a major problem in patients with hematologic malignancy." | 2.68 | Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. ( Schaffner, A; Schaffner, M, 1995) |
| "Fluconazole was found to be effective for preventing systemic fungal infections in neutropenic patients with cancer." | 2.68 | Prophylactic use of fluconazole in neutropenic cancer patients. ( Haznedar, R; Senol, E; Yamaç, K, 1995) |
| "Disseminated candidiasis is a serious infectious complication with a mortality as high as 50%." | 2.68 | An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. ( de Pauw, BE; Donnelly, JP; Kullberg, BJ; Meis, JF; Raemaekers, JM, 1995) |
| "Fluconazole has proved to be effective in treating oropharyngeal and esophageal candidiasis in immunocompromised patients." | 2.67 | Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. ( Akalin, HE; Akova, M; Aslan, S; Hayran, M; Kansu, E; Tekuzman, G; Telatar, H; Uzun, O, 1994) |
| "Fluconazole was particularly effective in reducing the carriage of C." | 2.67 | The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. ( Chandrasekar, PH; Gatny, CM, 1994) |
| "Fluconazole is a new orally absorbed antifungal azole which is effective in the treatment of mucosal and systemic infections caused by Candida, cryptococci and other fungi." | 2.67 | Management of fungal infection in neutropenic patients with fluconazole. ( Brammer, KW, 1990) |
| "The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs." | 2.66 | Breakthrough invasive fungal infections: Who is at risk? ( Chen, SC; Cornely, OA; Hoenigl, M; Jenks, JD; Thompson, GR, 2020) |
| "Most cases of deep-seated trichosporonosis develop in patients with neutropenia, but it has recently been reported that breakthrough infections with Trichosporon species can develop during the use of candin family of antifungal agents." | 2.52 | [Antifungal susceptibility and drug-resistant mechanism of Trichosporon]. ( Ishii, H; Kadota, J; Kushima, H; Tokimatsu, I, 2015) |
| "Invasive candidiasis is a frequent infection in compromised patient." | 2.41 | [Visceral candidiasis]. ( Herbrecht, R; Letscher-Bru, V; Zamfir, A, 2001) |
| "Opportunistic mycoses have emerged as important causes for morbidity and mortality in pediatric cancer patients, particularly in those with intensively treated hematological malignancies, allogeneic hematopoetic stem cell transplantation, and aplastic anemia." | 2.41 | [Prevention of fungal infections in children and adolescents with cancer]. ( Groll, AH; Müller, FM; Ritter, J, 2001) |
| "Patients with cancer complicated by neutropenia." | 2.40 | Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. ( Gøtzsche, PC; Johansen, HK, 1997) |
| " However, bioavailability of itraconazole is reduced in patients with raised gastric pH and no i." | 2.39 | [Prophylaxis against mycoses in neutropenic patients]. ( Arning, M; Aul, C, 1994) |
| "Amphotericin B has routinely been used to treat this infection." | 2.39 | Problems and controversies in the management of hematogenous candidiasis. ( Anaissie, EJ; Uzun, O, 1996) |
| "Fungal infections have emerged as a major complication of marrow transplantation in children." | 2.39 | Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. ( Chanock, SJ; Walsh, TJ, 1996) |
| "Over a 12 year period 19 children treated for leukemia at our institution developed C." | 2.38 | Candida tropicalis infections in children with leukemia. ( Flynn, PM; Hughes, WT; Marina, NM; Rivera, GK, 1993) |
| "Treatment with voriconazole was promptly started with success." | 1.43 | Acute isolated appendicitis due to Aspergillus carneus in a neutropenic child with acute myeloid leukemia. ( Bergami, E; Cavanna, C; Decembrino, N; Introzzi, F; Lallitto, F; Mangione, F; Marone, P; Tamarozzi, F; Tortorano, AM; Zecca, M, 2016) |
| "Most subjects (62%) had hematologic malignancies." | 1.39 | Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. ( Lloyd, L; Meibohm, A; Schuster, MG; Strom, B, 2013) |
| "Fluconazole was more frequently used in medium size hospitals than in the large ones (60." | 1.38 | [Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010]. ( Alvarez-Lerma, F; Gimeno-Costa, R; Gracia-Arnillas, MP; Insausti-Ordeñana, J; López-Pueyo, MJ; Olaechea-Astigarraga, PM; Otal-Entraigas, JJ; Palomar-Martínez, M; Seijas-Betolaza, I, 2012) |
| "Pulmonary aspergillosis was the most common causative agent, and no patients showed candidemia, or hepatosplenic candidiasis." | 1.37 | Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole. ( Kato, K; Kojima, S; Matsumoto, K; Watanabe, N, 2011) |
| "Treatment with amphotericin B(AMPH-B) and flucytosine(5-FC) was initiated as diagnosis of cryptococcus meningitis." | 1.37 | Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review. ( Ainoda, Y; Fujita, T; Hirai, Y; Mori, N; Motoji, T; Shiseki, M; Shoji, T; Teramura, M; Totsuka, K; Yoshinaga, K, 2011) |
| "glabrata fungemia were systematically recorded." | 1.36 | Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. ( Adrie, C; Clec'h, C; Cohen, Y; Gauzit, R; Karoubi, P; Marsepoil, T; Zarka, D, 2010) |
| "Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group)." | 1.36 | Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. ( Deremer, D; Dobbins, R; Eisa, N; El-Geneidy, M; Hall, P; Jillella, A; Lewis, G; Ustun, C, 2010) |
| "The aim of this study was to assess the dose-response of isavuconazole, voriconazole and fluconazole in disseminated Candida tropicalis and Candida krusei infections." | 1.35 | Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. ( Denning, DW; Majithiya, J; Parmar, A; Sharp, A; Warn, PA, 2009) |
| "Neutropenia was the leading risk factor for all candidemia, whereas the catheter was the leading risk factor for C." | 1.35 | The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. ( Hachem, R; Hanna, H; Jiang, Y; Kontoyiannis, D; Raad, I, 2008) |
| "Fluconazole was given as anti-Candida prophylaxis." | 1.34 | Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. ( Arai, S; Asai, T; Asano-Mori, Y; Chiba, S; Hangaishi, A; Hosoya, N; Izutsu, K; Kanda, Y; Kurokawa, M; Motokura, T; Nagai, S; Nishimoto, N; Oshima, K; Sato, H; Watanabe, T, 2007) |
| "While an AZ-based regimen is associated with increased cost, the reduced rate of nephrotoxicity and availability of oral dosage forms, suggests that azoles be used preferentially over AMB." | 1.34 | Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. ( Choe, L; Guglielmo, BJ; Inciardi, J; Martin, T; Riedel, A; Yuen, C, 2007) |
| "Mucormycosis was diagnosed in the neutropenic state following allogeneic hematopoietic cell transplantation (n=3) or intense chemotherapy (n=3)." | 1.33 | Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. ( Bethge, WA; Einsele, H; Hebart, H; Horger, M; Kanz, L; Kröber, SM; Schmalzing, M; Schumacher, U; Stuhler, G, 2005) |
| "In vivo studies have described the pharmacodynamic (PD) characteristics of several triazoles." | 1.32 | In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. ( Andes, D; Conklin, R; Marchillo, K; Stamstad, T, 2003) |
| "Fluconazole prophylaxis was not used during the study period." | 1.32 | Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. ( Anttila, VJ; Jantunen, E; Juvonen, E; Nihtinen, A; Parkkali, T; Ruutu, T; Volin, L, 2004) |
| " Long-term use of fluconazole may explain the outcome of the resistant stipple phenotype." | 1.31 | Phenotypic variation and antifungal susceptibility patterns of Candida albicans strains isolated from neutropenic patients. ( Akgün, Y; Anğ, O; Erturan, Z; Kiraz, N, 2000) |
| "Fluconazole was effective as a single agent in 3 patients with solid tumors." | 1.31 | Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. ( Hachem, R; Minari, A; Raad, I, 2001) |
| "Fluconazole, which has been available since the early 1990s, is a relatively atoxic intravenously applicable antimycotic agent." | 1.31 | [Retrospective analysis of fluconazole efficacy in Candida-colonized, non-neutropenic, surgical patients in long-term intensive care]. ( Böhrer, H; Kappe, R; Streitzig, S, 2001) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 1.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| "Fluconazole was less effective against C." | 1.31 | The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. ( Abbas, J; Bodey, GP; Boktour, M; Girgawy, E; Hachem, RY; Hanna, HA; Kontoyiannis, DP; Mardani, M; Raad, II, 2002) |
| "Voriconazole (UK-109,496) is a new triazole with in vitro activity against a wide spectrum of fungi including yeasts intrinsically resistant to fluconazole such as Candida krusei." | 1.30 | Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. ( Bhat, N; Ghannoum, MA; Okogbule-Wonodi, I; Sanati, H, 1999) |
| " The times spent above the MIC during the experimental dosing interval of 24 h were 4 h for LY at 0." | 1.30 | Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. ( Bacher, J; Bell, A; Candelario, M; Groll, AH; Lyman, CA; McMillian, CL; Petraitiene, R; Petraitis, V; Sein, T; Walsh, TJ, 1999) |
| "(NAC) in a single National Cancer Institution within 10 years were analysed for aetiology, risk factors and outcome." | 1.30 | Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. ( Grey, E; Jurga, L; Krcmery, V; Kunova, A; Mardiak, J; Mateicka, F; Mrazova, M; Novotny, J; Sabo, A; Sevcikova, L; Sorkovska, D; Sufliarsky, J; Trupl, J; West, D, 1999) |
| "This syndrome has a favorable prognosis." | 1.29 | A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. ( Hussein, A; Meisenberg, B; Mudad, R; Paulson, EK; Peters, WP; Ross, M; Vredenburgh, J, 1994) |
| "Treatment with fluconazole (100 mg/kg/day orally) had no effect." | 1.29 | SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice. ( Anaissie, EJ; Dignani, MC; Karyotakis, NC, 1995) |
| "Amphotericin B is the treatment of choice for acute and chronic hematogenously disseminated candidiasis." | 1.29 | Severe candidal infections in neutropenic patients. ( Edwards, JE; Filler, SG; Swerdloff, JN, 1993) |
| "Treatment with fluconazole alone also significantly lowered the number of C." | 1.28 | Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. ( Kullberg, BJ; Poell, RJ; van 't Wout, JW; van Furth, R, 1992) |
| "Amphotericin B was the most effective agent in this study of disseminated Candida tropicalis (C." | 1.28 | The comparative efficacy of cilofungin, fluconazole and amphotericin B in disseminated Candida tropicalis infection in neutropenic mice. ( Bannatyne, RM; Cheng, PC; Fong, IW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.50) | 18.7374 |
| 1990's | 83 (41.09) | 18.2507 |
| 2000's | 82 (40.59) | 29.6817 |
| 2010's | 32 (15.84) | 24.3611 |
| 2020's | 4 (1.98) | 2.80 |
| Authors | Studies |
|---|---|
| Chittick, P | 1 |
| Palavecino, EL | 1 |
| Delashmitt, B | 1 |
| Evans, J | 1 |
| Peacock, JE | 1 |
| Enger, K | 3 |
| Tonnar, X | 3 |
| Kotter, E | 3 |
| Bertz, H | 4 |
| Imatoh, T | 1 |
| Matsumoto, T | 1 |
| Haramaki, Y | 1 |
| Migita, K | 1 |
| Fisher, BT | 1 |
| Zaoutis, T | 1 |
| Dvorak, CC | 1 |
| Nieder, M | 1 |
| Zerr, D | 1 |
| Wingard, JR | 5 |
| Callahan, C | 1 |
| Villaluna, D | 1 |
| Chen, L | 1 |
| Dang, H | 1 |
| Esbenshade, AJ | 1 |
| Alexander, S | 1 |
| Wiley, JM | 1 |
| Sung, L | 1 |
| Monzani, V | 1 |
| Córdoba, S | 1 |
| Vivot, M | 1 |
| Arias, B | 1 |
| Vivot, W | 1 |
| Szusz, W | 1 |
| Castellaro, P | 1 |
| Appendino, A | 1 |
| Taverna, CG | 1 |
| Jenks, JD | 1 |
| Cornely, OA | 3 |
| Chen, SC | 1 |
| Thompson, GR | 1 |
| Hoenigl, M | 1 |
| van Prehn, J | 1 |
| Menke-van der Houven van Oordt, CW | 1 |
| de Rooij, ML | 1 |
| Meijer, E | 1 |
| Bomers, MK | 1 |
| van Dijk, K | 1 |
| Goel, G | 1 |
| Chandy, M | 1 |
| Bhattacharyya, A | 1 |
| Banerjee, S | 1 |
| Chatterjee, S | 1 |
| Mullick, S | 1 |
| Sinha, S | 1 |
| Sengupta, K | 1 |
| Dhar, K | 1 |
| Bhattacharya, S | 1 |
| Rudramurthy, S | 1 |
| Chakrabarti, A | 1 |
| Ko, JH | 1 |
| Peck, KR | 1 |
| Jung, DS | 1 |
| Lee, JY | 1 |
| Kim, HA | 1 |
| Ryu, SY | 1 |
| Jung, SI | 1 |
| Joo, EJ | 1 |
| Cheon, S | 1 |
| Kim, YS | 1 |
| Kim, SW | 1 |
| Cho, SY | 1 |
| Ha, YE | 1 |
| Kang, CI | 1 |
| Chung, DR | 1 |
| Lee, NY | 1 |
| Song, JH | 1 |
| Athanasakis, K | 1 |
| Petrakis, I | 1 |
| Kyriopoulos, J | 1 |
| Blennow, O | 1 |
| Ljungman, P | 1 |
| Sparrelid, E | 1 |
| Mattsson, J | 1 |
| Remberger, M | 1 |
| Lourdes, LS | 1 |
| Mitchell, CL | 1 |
| Glavin, FL | 1 |
| Schain, DC | 1 |
| Kaye, FJ | 1 |
| Jørgensen, KJ | 2 |
| Gøtzsche, PC | 5 |
| Dalbøge, CS | 1 |
| Johansen, HK | 7 |
| Lundberg, J | 1 |
| Höglund, M | 1 |
| Björkholm, M | 1 |
| Åkerborg, Ö | 1 |
| Zilberberg, M | 1 |
| Yu, HT | 1 |
| Chaudhari, P | 1 |
| Emons, MF | 1 |
| Khandelwal, N | 1 |
| Shorr, AF | 1 |
| Döring, M | 1 |
| Eikemeier, M | 1 |
| Cabanillas Stanchi, KM | 1 |
| Hartmann, U | 1 |
| Ebinger, M | 1 |
| Schwarze, CP | 1 |
| Schulz, A | 1 |
| Handgretinger, R | 1 |
| Müller, I | 1 |
| Kushima, H | 2 |
| Tokimatsu, I | 2 |
| Ishii, H | 2 |
| Kadota, J | 2 |
| Decembrino, N | 1 |
| Zecca, M | 1 |
| Tortorano, AM | 1 |
| Mangione, F | 1 |
| Lallitto, F | 1 |
| Introzzi, F | 1 |
| Bergami, E | 1 |
| Marone, P | 1 |
| Tamarozzi, F | 1 |
| Cavanna, C | 1 |
| Rammaert, B | 1 |
| Candon, S | 1 |
| Maunoury, C | 1 |
| Bougnoux, ME | 1 |
| Jouvion, G | 1 |
| Braun, T | 1 |
| Correas, JM | 1 |
| Lortholary, O | 2 |
| Durán Graeff, L | 1 |
| Seidel, D | 1 |
| Vehreschild, MJ | 1 |
| Hamprecht, A | 1 |
| Kindo, A | 1 |
| Racil, Z | 1 |
| Demeter, J | 1 |
| De Hoog, S | 1 |
| Aurbach, U | 1 |
| Ziegler, M | 1 |
| Wisplinghoff, H | 1 |
| Karthaus, M | 2 |
| Fekete, T | 1 |
| Stam, WB | 1 |
| O'Sullivan, AK | 1 |
| Rijnders, B | 1 |
| Lugtenburg, E | 1 |
| Span, LF | 1 |
| Janssen, JJ | 1 |
| Jansen, JP | 1 |
| Majithiya, J | 1 |
| Sharp, A | 2 |
| Parmar, A | 1 |
| Denning, DW | 3 |
| Warn, PA | 2 |
| Collins, CD | 1 |
| Ellis, JJ | 1 |
| Kaul, DR | 1 |
| Hiramatsu, Y | 1 |
| Maeda, Y | 1 |
| Fujii, N | 1 |
| Saito, T | 1 |
| Nawa, Y | 1 |
| Hara, M | 1 |
| Yano, T | 1 |
| Asakura, S | 1 |
| Sunami, K | 1 |
| Tabayashi, T | 1 |
| Miyata, A | 1 |
| Matsuoka, KI | 1 |
| Shinagawa, K | 1 |
| Ikeda, K | 1 |
| Matsuo, K | 1 |
| Tanimoto, M | 1 |
| Almirante, B | 1 |
| Pemán, J | 1 |
| Slobbe, L | 1 |
| Waal, Lv | 1 |
| Jongman, LR | 1 |
| Lugtenburg, PJ | 1 |
| Rijnders, BJ | 1 |
| Wang, J | 1 |
| Zhan, P | 1 |
| Zhou, R | 1 |
| Xu, J | 2 |
| Shao, X | 1 |
| Yang, Y | 1 |
| Ouyang, J | 1 |
| Cohen, Y | 1 |
| Karoubi, P | 1 |
| Adrie, C | 1 |
| Gauzit, R | 1 |
| Marsepoil, T | 1 |
| Zarka, D | 1 |
| Clec'h, C | 1 |
| Sawada, A | 1 |
| Sakata, N | 1 |
| Higuchi, B | 1 |
| Takeshita, Y | 1 |
| Ishihara, T | 1 |
| Sakata, A | 1 |
| Kouroki, M | 1 |
| Kondo, O | 1 |
| Koyama, M | 1 |
| Hirano, S | 1 |
| Yasui, M | 1 |
| Inoue, M | 1 |
| Yoshioka, A | 1 |
| Kawa, K | 1 |
| Sobel, JD | 2 |
| Krishnan-Natesan, S | 1 |
| Manavathu, EK | 1 |
| Cutright, JL | 1 |
| Chandrasekar, PH | 4 |
| Sobrevilla Calvo, P | 1 |
| Lazzaro, C | 1 |
| Lewis, G | 1 |
| Hall, P | 1 |
| Eisa, N | 1 |
| Deremer, D | 1 |
| Dobbins, R | 1 |
| El-Geneidy, M | 1 |
| Jillella, A | 1 |
| Ustun, C | 1 |
| Póvoa, P | 1 |
| Gonçalves-Pereira, J | 1 |
| Watanabe, N | 1 |
| Matsumoto, K | 1 |
| Kojima, S | 1 |
| Kato, K | 1 |
| Hirai, Y | 1 |
| Ainoda, Y | 1 |
| Shoji, T | 1 |
| Fujita, T | 1 |
| Yoshinaga, K | 1 |
| Shiseki, M | 1 |
| Mori, N | 1 |
| Teramura, M | 1 |
| Totsuka, K | 1 |
| Motoji, T | 1 |
| Wiederhold, NP | 1 |
| Najvar, LK | 2 |
| Bocanegra, R | 1 |
| Kirkpatrick, WR | 1 |
| Patterson, TF | 1 |
| Olaechea-Astigarraga, PM | 1 |
| Alvarez-Lerma, F | 1 |
| Palomar-Martínez, M | 1 |
| Insausti-Ordeñana, J | 1 |
| López-Pueyo, MJ | 1 |
| Seijas-Betolaza, I | 1 |
| Otal-Entraigas, JJ | 1 |
| Gimeno-Costa, R | 1 |
| Gracia-Arnillas, MP | 1 |
| Szilágyi, J | 1 |
| Földi, R | 1 |
| Gesztelyi, R | 1 |
| Bayegan, S | 1 |
| Kardos, G | 1 |
| Juhász, B | 1 |
| Majoros, L | 1 |
| Schuster, MG | 2 |
| Meibohm, A | 1 |
| Lloyd, L | 1 |
| Strom, B | 1 |
| Beam, E | 1 |
| Mansfield, AS | 1 |
| Thompson, CA | 1 |
| Rex, JH | 3 |
| Pappas, PG | 3 |
| Karchmer, AW | 2 |
| Sobel, J | 1 |
| Edwards, JE | 4 |
| Hadley, S | 1 |
| Brass, C | 1 |
| Vazquez, JA | 1 |
| Chapman, SW | 1 |
| Horowitz, HW | 2 |
| Zervos, M | 1 |
| McKinsey, D | 1 |
| Lee, J | 1 |
| Babinchak, T | 1 |
| Bradsher, RW | 1 |
| Cleary, JD | 1 |
| Cohen, DM | 1 |
| Danziger, L | 1 |
| Goldman, M | 1 |
| Goodman, J | 1 |
| Hilton, E | 1 |
| Hyslop, NE | 1 |
| Kett, DH | 1 |
| Lutz, J | 1 |
| Rubin, RH | 1 |
| Scheld, WM | 2 |
| Schuster, M | 1 |
| Simmons, B | 1 |
| Stein, DK | 1 |
| Washburn, RG | 2 |
| Mautner, L | 1 |
| Chu, TC | 1 |
| Panzer, H | 1 |
| Rosenstein, RB | 1 |
| Booth, J | 1 |
| Van Saene, HK | 1 |
| Silvestri, L | 1 |
| Petros, A | 1 |
| Viviani, M | 1 |
| de la Cal, MA | 1 |
| Zandstra, DF | 1 |
| Myoken, Y | 5 |
| Kyo, T | 4 |
| Kohara, T | 1 |
| Fujihara, M | 4 |
| Sugata, T | 4 |
| Mikami, Y | 4 |
| McGee, WT | 1 |
| Tereso, GJ | 1 |
| Gottfredsson, M | 1 |
| Vredenburgh, JJ | 1 |
| Schell, WA | 1 |
| Perfect, JR | 1 |
| Preston, SL | 1 |
| Briceland, LL | 1 |
| Andes, D | 2 |
| Marchillo, K | 1 |
| Stamstad, T | 1 |
| Conklin, R | 1 |
| Mikamo, H | 1 |
| Ninomiya, M | 1 |
| Tamaya, T | 1 |
| Höhl, R | 1 |
| Hernandez, S | 1 |
| Gonzalez, GM | 1 |
| McCarthy, DI | 1 |
| Colombo, AL | 2 |
| Bocanegera, R | 1 |
| Graybill, JR | 3 |
| Stemmer, SM | 1 |
| Maor, Y | 1 |
| Hardan, I | 1 |
| Jantunen, E | 1 |
| Nihtinen, A | 1 |
| Volin, L | 1 |
| Juvonen, E | 1 |
| Parkkali, T | 1 |
| Ruutu, T | 1 |
| Anttila, VJ | 1 |
| van Burik, JA | 1 |
| Ratanatharathorn, V | 1 |
| Stepan, DE | 1 |
| Miller, CB | 2 |
| Lipton, JH | 1 |
| Vesole, DH | 1 |
| Bunin, N | 1 |
| Wall, DA | 1 |
| Hiemenz, JW | 1 |
| Satoi, Y | 1 |
| Lee, JM | 1 |
| Walsh, TJ | 5 |
| Menichetti, F | 2 |
| Yoshida, M | 1 |
| Minenko, SV | 1 |
| Zhukov, NV | 1 |
| Chimishkian, KL | 1 |
| Sokolova, EN | 1 |
| Ptushkin, VV | 1 |
| Morrissey, G | 1 |
| Glasmacher, A | 3 |
| Prentice, AG | 1 |
| Vardakas, KZ | 1 |
| Michalopoulos, A | 1 |
| Falagas, ME | 1 |
| Luzzati, R | 1 |
| Allegranzi, B | 1 |
| Antozzi, L | 1 |
| Masala, L | 1 |
| Pegoraro, E | 1 |
| Azzini, A | 1 |
| Concia, E | 1 |
| Colombo, GL | 1 |
| Morlotti, L | 1 |
| Serra, G | 1 |
| Bethge, WA | 1 |
| Schmalzing, M | 1 |
| Stuhler, G | 1 |
| Schumacher, U | 2 |
| Kröber, SM | 1 |
| Horger, M | 1 |
| Einsele, H | 2 |
| Kanz, L | 2 |
| Hebart, H | 2 |
| Cornely, O | 1 |
| Ullmann, AJ | 3 |
| Wedding, U | 1 |
| Bodenstein, H | 1 |
| Wandt, H | 1 |
| Boewer, C | 1 |
| Pasold, R | 1 |
| Wolf, HH | 1 |
| Hänel, M | 1 |
| Dölken, G | 1 |
| Junghanss, C | 1 |
| Andreesen, R | 1 |
| Halliday, C | 1 |
| Hoile, R | 1 |
| Sorrell, T | 1 |
| James, G | 1 |
| Yadav, S | 1 |
| Shaw, P | 1 |
| Bleakley, M | 1 |
| Bradstock, K | 1 |
| Chen, S | 1 |
| Oren, I | 1 |
| Rowe, JM | 1 |
| Sprecher, H | 1 |
| Tamir, A | 1 |
| Benyamini, N | 1 |
| Akria, L | 1 |
| Gorelik, A | 1 |
| Dally, N | 1 |
| Zuckerman, T | 1 |
| Haddad, N | 1 |
| Fineman, R | 1 |
| Dann, EJ | 1 |
| Gumbo, T | 1 |
| Drusano, GL | 1 |
| Liu, W | 1 |
| Ma, L | 1 |
| Deziel, MR | 1 |
| Drusano, MF | 1 |
| Louie, A | 1 |
| Yu, DT | 1 |
| Seger, DL | 1 |
| Peterson, JF | 1 |
| Kumar, RN | 1 |
| Bates, DW | 1 |
| Hashinaga, K | 1 |
| Umeki, K | 1 |
| Ohama, M | 1 |
| Kishi, K | 1 |
| Hiramatsu, K | 1 |
| Nakagawa, Y | 1 |
| Maertens, J | 1 |
| Winston, DJ | 3 |
| Perfect, J | 1 |
| Helfgott, D | 1 |
| Holowiecki, J | 1 |
| Stockelberg, D | 1 |
| Goh, YT | 1 |
| Petrini, M | 1 |
| Hardalo, C | 1 |
| Suresh, R | 1 |
| Angulo-Gonzalez, D | 1 |
| De Pauw, BE | 4 |
| Donnelly, JP | 3 |
| Pazos, C | 1 |
| Moragues, MD | 1 |
| Quindós, G | 1 |
| Pontón, J | 1 |
| del Palacio, A | 1 |
| Oshima, K | 1 |
| Kanda, Y | 2 |
| Asano-Mori, Y | 1 |
| Nishimoto, N | 1 |
| Arai, S | 1 |
| Nagai, S | 1 |
| Sato, H | 2 |
| Watanabe, T | 1 |
| Hosoya, N | 1 |
| Izutsu, K | 1 |
| Asai, T | 1 |
| Hangaishi, A | 1 |
| Motokura, T | 1 |
| Chiba, S | 1 |
| Kurokawa, M | 1 |
| Riedel, A | 1 |
| Choe, L | 1 |
| Inciardi, J | 1 |
| Yuen, C | 1 |
| Martin, T | 1 |
| Guglielmo, BJ | 1 |
| Lupetti, A | 1 |
| Brouwer, CP | 1 |
| Bogaards, SJ | 1 |
| Welling, MM | 1 |
| de Heer, E | 1 |
| Campa, M | 1 |
| van Dissel, JT | 1 |
| Friesen, RH | 1 |
| Nibbering, PH | 1 |
| de Vries, R | 1 |
| Daenen, S | 1 |
| Tolley, K | 1 |
| Prentice, A | 1 |
| Howells, S | 1 |
| Christopherson, H | 1 |
| de Jong-van den Berg, LT | 1 |
| Postma, MJ | 1 |
| Gonzalez, AV | 1 |
| Almyroudis, NG | 1 |
| Segal, BH | 1 |
| Nomura, S | 1 |
| Iishii, K | 1 |
| Inami, N | 1 |
| Kimura, E | 1 |
| Urase, F | 1 |
| Hachem, R | 4 |
| Hanna, H | 1 |
| Kontoyiannis, D | 1 |
| Jiang, Y | 1 |
| Raad, I | 3 |
| Kersun, LS | 1 |
| Reilly, AF | 1 |
| Ingram, ME | 1 |
| Nicholaou, MJ | 1 |
| McGowan, KL | 1 |
| Mudad, R | 1 |
| Vredenburgh, J | 1 |
| Paulson, EK | 1 |
| Ross, M | 1 |
| Meisenberg, B | 1 |
| Hussein, A | 1 |
| Peters, WP | 1 |
| Arning, M | 1 |
| Aul, C | 1 |
| Schaffner, A | 2 |
| Schaffner, M | 1 |
| Kunová, A | 3 |
| Trupl, J | 3 |
| Dluholucký, S | 1 |
| Galová, G | 1 |
| Krcméry, V | 5 |
| Yamaç, K | 1 |
| Senol, E | 1 |
| Haznedar, R | 1 |
| Ellis, ME | 3 |
| Halim, MA | 3 |
| Spence, D | 3 |
| Ernst, P | 3 |
| Clink, H | 3 |
| Kalin, M | 2 |
| Baillie, F | 2 |
| Greer, W | 2 |
| Egger, T | 1 |
| Gratwohl, A | 1 |
| Tichelli, A | 1 |
| Uhr, M | 1 |
| Stebler Gysi, C | 1 |
| Passweg, J | 1 |
| Pless, M | 1 |
| Wernli, M | 1 |
| Buser, U | 1 |
| Wuhrmann, J | 1 |
| Sugar, AM | 2 |
| Hitchcock, CA | 1 |
| Troke, PF | 1 |
| Picard, M | 1 |
| Karyotakis, NC | 2 |
| Dignani, MC | 2 |
| Anaissie, EJ | 3 |
| Raemaekers, JM | 1 |
| Kullberg, BJ | 2 |
| Meis, JF | 3 |
| Martino, P | 2 |
| Girmenia, C | 1 |
| Micozzi, A | 2 |
| De Bernardis, F | 1 |
| Boccanera, M | 1 |
| Cassone, A | 1 |
| Qadri, SM | 1 |
| De Vol, EB | 1 |
| Fukuda, M | 1 |
| Hirashima, K | 1 |
| Kurane, R | 1 |
| Abe, T | 1 |
| Sampi, K | 1 |
| Tominaga, K | 1 |
| Tsuji, M | 1 |
| Takagi, S | 1 |
| Naito, T | 1 |
| Bennett, JE | 1 |
| van der Horst, CM | 1 |
| Dine, AP | 1 |
| Meunier, F | 1 |
| Chubachi, A | 2 |
| Miura, I | 2 |
| Ohshima, A | 2 |
| Nishinari, T | 1 |
| Nimura, T | 2 |
| Niitsu, H | 2 |
| Miura, AB | 2 |
| Akova, M | 2 |
| Akalin, HE | 1 |
| Uzun, O | 2 |
| Hayran, M | 2 |
| Tekuzman, G | 1 |
| Kansu, E | 1 |
| Aslan, S | 1 |
| Telatar, H | 1 |
| Pahls, S | 1 |
| Padmos, A | 1 |
| Hussain Qadri, SM | 1 |
| Burnie, J | 1 |
| van Belkum, A | 2 |
| Melchers, W | 1 |
| Scherer, S | 1 |
| Quint, W | 1 |
| Del Favero, A | 1 |
| Bucaneve, G | 1 |
| D'Antonio, D | 1 |
| Ricci, P | 1 |
| Carotenuto, M | 1 |
| Liso, V | 1 |
| Nosari, AM | 1 |
| Barbui, T | 1 |
| Fasola, G | 1 |
| Mandelli, F | 1 |
| Akiyama, H | 2 |
| Mori, S | 1 |
| Tanikawa, S | 1 |
| Sakamaki, H | 1 |
| Onozawa, Y | 1 |
| Gatny, CM | 1 |
| Flynn, PM | 1 |
| Marina, NM | 1 |
| Rivera, GK | 1 |
| Hughes, WT | 1 |
| Samonis, G | 1 |
| Merz, WG | 1 |
| Rinaldi, MG | 1 |
| Karp, JE | 1 |
| Saral, R | 1 |
| Swerdloff, JN | 1 |
| Filler, SG | 2 |
| Philpott-Howard, JN | 1 |
| Wade, JJ | 1 |
| Mufti, GJ | 1 |
| Brammer, KW | 2 |
| Ehninger, G | 1 |
| Ong, ST | 1 |
| Kueh, YK | 1 |
| Lazarus, HM | 1 |
| Goodman, JL | 1 |
| Silber, JL | 1 |
| Horowitz, H | 1 |
| Shadduck, RK | 1 |
| Rosenfeld, CS | 1 |
| Ho, WG | 1 |
| Islam, MZ | 1 |
| Buell, DN | 1 |
| Stark, A | 1 |
| Dale, B | 1 |
| Toolis, F | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Balcerska, A | 1 |
| Drozyńska, E | 1 |
| Stefanowicz, J | 1 |
| Bień, E | 1 |
| Szutowicz, E | 1 |
| Czarniak, P | 1 |
| Chanock, SJ | 1 |
| Velegraki, A | 1 |
| Papalambrou, D | 1 |
| Soremi, S | 1 |
| Legakis, NJ | 1 |
| Holmgren, D | 1 |
| Seiter, K | 1 |
| Kitamura, K | 1 |
| Miyagawa, K | 1 |
| Urabe, A | 1 |
| Obayashi, Y | 1 |
| Aoki, I | 1 |
| Takaku, F | 1 |
| Togawa, A | 2 |
| Shindou, E | 1 |
| Wakabayashi, Y | 1 |
| Ohshima, T | 1 |
| Horikoshi, A | 1 |
| Nomura, T | 1 |
| Ohki, I | 1 |
| Suzuki, K | 1 |
| Kamakura, M | 1 |
| Oguchi, A | 1 |
| Toyama, K | 1 |
| Yaguchi, M | 1 |
| Aoki, N | 1 |
| Kato, A | 1 |
| Mizoguchi, H | 1 |
| Masuda, M | 1 |
| Irie, S | 1 |
| Fujioka, S | 1 |
| Roller, G | 1 |
| Löffler, J | 1 |
| Rothenhofer, I | 1 |
| Müller, CA | 1 |
| Bowden, RA | 1 |
| van Burik, J | 1 |
| Engelhard, D | 1 |
| Sanati, H | 2 |
| Ramos, CF | 1 |
| Bayer, AS | 1 |
| Ghannoum, MA | 2 |
| Piemonte, P | 1 |
| Conte, G | 1 |
| Flores, C | 1 |
| Barahona, O | 1 |
| Araos, D | 1 |
| Alfaro, J | 1 |
| Fardella, P | 1 |
| Thompson, L | 1 |
| Odds, FC | 1 |
| Burgaleta, C | 1 |
| Arikan, S | 1 |
| Ozdemir, O | 1 |
| Erman, M | 1 |
| Gür, D | 1 |
| Unal, S | 1 |
| Krupova, I | 1 |
| Kaiserova, E | 1 |
| Foltinova, A | 1 |
| Kovacicova, G | 1 |
| Kiskova, M | 1 |
| Krchnakova, A | 1 |
| West, D | 2 |
| Nouwen, JL | 1 |
| de Marie, S | 1 |
| Sluijs, J | 1 |
| Wielenga, JJ | 1 |
| Kluytmans, JA | 1 |
| Verbrugh, HA | 1 |
| Malik, IA | 1 |
| Moid, I | 1 |
| Aziz, Z | 1 |
| Khan, S | 1 |
| Suleman, M | 1 |
| Krupova, Y | 1 |
| Novotny, J | 2 |
| Sabo, A | 2 |
| Mateicka, F | 2 |
| Rotstein, C | 2 |
| Bow, EJ | 2 |
| Laverdiere, M | 2 |
| Ioannou, S | 2 |
| Carr, D | 2 |
| Moghaddam, N | 2 |
| Okogbule-Wonodi, I | 1 |
| Bhat, N | 1 |
| Hoban, DJ | 1 |
| Zhanel, GG | 1 |
| Karlowsky, JA | 1 |
| Takatsuka, H | 1 |
| Takemoto, Y | 1 |
| Okamoto, T | 1 |
| Fujimori, Y | 1 |
| Tamura, S | 1 |
| Wada, H | 1 |
| Okada, M | 1 |
| Kanamaru, A | 1 |
| Kakishita, E | 1 |
| Colović, M | 1 |
| Lazarević, V | 1 |
| Colović, R | 1 |
| Janković, G | 1 |
| Suvajdzić, N | 1 |
| Bogdanović, A | 1 |
| Bila, J | 1 |
| van Ogtrop, M | 1 |
| Petraitiene, R | 1 |
| Petraitis, V | 1 |
| Groll, AH | 2 |
| Candelario, M | 1 |
| Sein, T | 1 |
| Bell, A | 1 |
| Lyman, CA | 1 |
| McMillian, CL | 1 |
| Bacher, J | 1 |
| Mrazova, M | 1 |
| Grey, E | 1 |
| Mardiak, J | 2 |
| Jurga, L | 1 |
| Sufliarsky, J | 2 |
| Sevcikova, L | 1 |
| Sorkovska, D | 1 |
| Huijgens, PC | 3 |
| Simoons-Smit, AM | 3 |
| van Loenen, AC | 3 |
| Prooy, E | 1 |
| van Tinteren, H | 1 |
| Ossenkoppele, GJ | 1 |
| Jonkhoff, AR | 1 |
| Gotzsche, PC | 2 |
| Offidani, M | 1 |
| Corvatta, L | 1 |
| Olivieri, A | 1 |
| Rupoli, S | 1 |
| Frayfer, J | 1 |
| Mele, A | 1 |
| Manso, E | 1 |
| Montanari, M | 1 |
| Centurioni, R | 1 |
| Leoni, P | 1 |
| Young, GA | 1 |
| Bosly, A | 1 |
| Gibbs, DL | 1 |
| Durrant, S | 1 |
| Timmers, GJ | 2 |
| Goranov, S | 1 |
| Spasov, E | 1 |
| Grudeva-Popova, J | 1 |
| Vakrilov, V | 1 |
| Wolff, SN | 1 |
| Fay, J | 1 |
| Stevens, D | 1 |
| Herzig, RH | 1 |
| Pohlman, B | 1 |
| Bolwell, B | 1 |
| Lynch, J | 1 |
| Ericson, S | 1 |
| Freytes, CO | 1 |
| LeMaistre, F | 1 |
| Collins, R | 1 |
| Pineiro, L | 1 |
| Greer, J | 1 |
| Stein, R | 1 |
| Goodman, SA | 1 |
| Dummer, S | 1 |
| Zweegman, S | 1 |
| Touw, D | 1 |
| Silling, G | 1 |
| Fegeler, W | 1 |
| Roos, N | 1 |
| Essink, M | 1 |
| Büchner, T | 1 |
| Böhme, A | 1 |
| Hoelzer, D | 1 |
| Kiraz, N | 1 |
| Anğ, O | 1 |
| Akgün, Y | 1 |
| Erturan, Z | 1 |
| Salonen, JH | 1 |
| Richardson, MD | 1 |
| Gallacher, K | 1 |
| Issakainen, J | 1 |
| Helenius, H | 1 |
| Lehtonen, OP | 1 |
| Nikoskelainen, J | 1 |
| Abbas, J | 2 |
| Bodey, GP | 3 |
| Hanna, HA | 2 |
| Mardani, M | 2 |
| Girgawy, E | 2 |
| Abi-Said, D | 1 |
| Whimbey, E | 1 |
| Yamamoto, R | 1 |
| Chizuka, A | 1 |
| Hamaki, T | 1 |
| Suguro, M | 1 |
| Arai, C | 1 |
| Matsuyama, T | 1 |
| Takezako, N | 1 |
| Miwa, A | 1 |
| Kern, W | 1 |
| Kami, M | 1 |
| Hirai, H | 1 |
| Hathorn, JW | 1 |
| Schiller, GJ | 1 |
| Territo, MC | 1 |
| Roberts, RS | 1 |
| Paterson, PJ | 1 |
| McWhinney, PH | 1 |
| Potter, M | 1 |
| Kibbler, CC | 1 |
| Prentice, HG | 1 |
| Minari, A | 1 |
| Dismukes, WE | 1 |
| Persson, L | 1 |
| Vikerfors, T | 1 |
| Sjöberg, L | 1 |
| Engervall, P | 1 |
| Tidefelt, U | 1 |
| Segal, RE | 1 |
| Minamoto, GY | 1 |
| Herbrecht, R | 1 |
| Zamfir, A | 1 |
| Letscher-Bru, V | 1 |
| André, MH | 1 |
| Kappe, R | 1 |
| Streitzig, S | 1 |
| Böhrer, H | 1 |
| Ritter, J | 1 |
| Müller, FM | 1 |
| McKelvie, PA | 1 |
| Wong, EY | 1 |
| Chow, LP | 1 |
| Hall, AJ | 1 |
| Marr, KA | 1 |
| Safdar, A | 1 |
| van Rhee, F | 1 |
| Henslee-Downey, JP | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Boktour, M | 1 |
| Hachem, RY | 1 |
| Kontoyiannis, DP | 1 |
| Raad, II | 1 |
| Nucci, M | 1 |
| Lee, DG | 1 |
| Choi, SM | 1 |
| Choi, JH | 1 |
| Yoo, JH | 1 |
| Park, YH | 1 |
| Kim, YJ | 1 |
| Lee, S | 1 |
| Min, CK | 1 |
| Kim, HJ | 1 |
| Kim, DW | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Shin, WS | 1 |
| Kim, CC | 1 |
| van 't Wout, JW | 1 |
| Poell, RJ | 1 |
| van Furth, R | 2 |
| Fong, IW | 1 |
| Bannatyne, RM | 1 |
| Cheng, PC | 1 |
| Broughton, BJ | 1 |
| Soutar, RL | 1 |
| Colville, A | 1 |
| Wale, MC | 1 |
| Bignardi, GE | 1 |
| Savage, MA | 1 |
| Coker, R | 1 |
| Davis, SG | 1 |
| Koza, I | 1 |
| Hornikova, M | 1 |
| Fuchsberger, P | 1 |
| Spanik, S | 1 |
| Blahova, M | 1 |
| Savko, V | 1 |
| Migom, C | 1 |
| McIlroy, MA | 1 |
| Muñoz, P | 1 |
| Moreno, S | 1 |
| Garau, X | 1 |
| López Bernaldo de Quirós, JC | 1 |
| Berenguer, J | 1 |
| More, J | 1 |
| Bouza, E | 1 |
| Finke, R | 1 |
| Schaison, G | 1 |
| Baruchel, A | 1 |
| Arlet, G | 1 |
| Van t Wout, JW | 1 |
| Mattie, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)[NCT01307579] | Phase 3 | 517 participants (Actual) | Interventional | 2011-04-04 | Completed | ||
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients[NCT00044486] | Phase 3 | 602 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Revision of Antifungal Strategies Definitions for Invasive Fungal Infections (Proven/Probable/Possible) in Patients With Hematological Malignancies (REDEFI-SEIFEM)[NCT04024995] | 513 participants (Actual) | Observational [Patient Registry] | 2019-09-01 | Completed | |||
| Invasive Fungal Infections in Patients Following Stem Cell Transplant[NCT04619147] | 300 participants (Anticipated) | Observational | 2021-01-31 | Not yet recruiting | |||
| ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis[NCT00723073] | 323 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection[NCT00388167] | 320 participants (Anticipated) | Observational | 2004-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Kaplan Meier method will be used to estimate overall survival. Time to event is from enrollment to date of death (by any cause). Participants are censored at last contact or 2 years anniversary of enrollment into this study, whichever occurred first. (NCT01307579)
Timeframe: Up to 2 years post enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 68.8 |
| Arm II (Fluconazole) | 70.8 |
The percentage of participants requiring empiric antifungal therapy will be determined based on the presence of prolonged fever and neutropenia during each neutropenia course. (NCT01307579)
Timeframe: Up to 5 months since enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 71.9 |
| Arm II (Fluconazole) | 69.5 |
Proven or probable invasive aspergillosis (IA) is defined according to the criteria developed by the EORTC/MSG. Kaplan Meier approach will used to estimate the incidence. (NCT01307579)
Timeframe: Up to 5 months since enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 0.5 |
| Arm II (Fluconazole) | 3.1 |
Proven or probable IFI is defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG). (NCT01307579)
Timeframe: Up to 5 months since enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm I (Caspofungin Acetate) | 3.1 |
| Arm II (Fluconazole) | 7.2 |
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
median duration of therapy with an echinocandin (caspofungin or micafungin) for persistent febrile neutropenia (FN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 10 |
| Micafungin Arm | 9 |
Median number of days patients were hospitalized during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 29 |
| Micafungin Arm | 28 |
Median number of days patients were neutropenic during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 20 |
| Micafungin Arm | 17 |
a breakthrough invasive fungal disesase was defined as any fungal infection that was diagnosed > 3 days on or during therapy or within 7 days after completion of therapy with an echinocandin (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| No breakthrough IFD | Breakthrough IFD | |
| Caspofungin Arm | 133 | 16 |
| Micafungin Arm | 153 | 21 |
Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy. (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Caspofungin Arm | 122 | 27 |
| Micafungin Arm | 141 | 33 |
Defined as any advsere event directly attributable to echinocandin treatment that led to discontinuation of therapy or switch to alternative therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| No ADE | ADE which caused EC therapy discontinuation | |
| Caspofungin Arm | 146 | 3 |
| Micafungin Arm | 172 | 2 |
aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 5x the upper limit of normal (ULN) or total bilirubin > 3x the upper limit of normal (ULN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No LFT elevations | AST > 5x upper limit of normal | ALT > 5x upper limit of normal | Total Bilirubin >3x upper limit of normal | |
| Caspofungin Arm | 110 | 14 | 10 | 15 |
| Micafungin Arm | 132 | 15 | 9 | 18 |
We assessed all patients in the study cohort who dischaged from the hospital alive (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| Alive at hospital discharge | Died before hospitial discharge | |
| Caspofungin Arm | 137 | 12 |
| Micafungin Arm | 161 | 13 |
The description of the adverse event that resulted in discontinuation of echinocandin (EC) therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No Adverse Event requiring EC discontinuation | Rash | Liver function Test (LFT) increase | Anaphylaxis | |
| Caspofungin Arm | 146 | 2 | 0 | 1 |
| Micafungin Arm | 172 | 1 | 1 | 0 |
Possible or proven baseline invasive fungal disease were defined as were diagnosed within the 2 days of initiating echinocandin therapy for persistent febrile neutropenia (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | ||
|---|---|---|---|
| No Baseline IFD | Successfully treated baseline IFD | Unsuccessfully treated baseline IFD | |
| Caspofungin Arm | 146 | 2 | 1 |
| Micafungin Arm | 168 | 4 | 2 |
34 reviews available for fluconazole and Neutropenia
| Article | Year |
|---|---|
Breakthrough invasive fungal infections: Who is at risk?
Topics: Adrenal Cortex Hormones; Antifungal Agents; Aspergillus; Candida; Central Venous Catheters; Echinoca | 2020 |
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Fluconazole; Humans; Liposomes; Mycoses; Neoplasms | 2014 |
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Confidence Intervals; Fluconazole; Humans; | 2014 |
[Antifungal susceptibility and drug-resistant mechanism of Trichosporon].
Topics: Antifungal Agents; Azoles; Drug Resistance, Fungal; Fluconazole; Microbial Sensitivity Tests; Neutro | 2015 |
[Current treatment of candidemia. Role of anidulafungin].
Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis; Clinical Trials as Topic; Disease Suscep | 2008 |
Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; | 2010 |
[Fungal infections in oncohematology: the role of prophylaxis].
Topics: Antifungal Agents; Antineoplastic Agents; Fever; Fluconazole; Hematologic Neoplasms; Humans; Mycoses | 2010 |
Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.
Topics: Adult; Amphotericin B; Animals; Antifungal Agents; Candidemia; Echinocandins; Fluconazole; Fungal Pr | 2011 |
Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia.
Topics: Antifungal Agents; Clinical Trials as Topic; Fluconazole; Humans; Mycoses; Neutropenia | 1995 |
[New therapeutical options for pulmonary fungal infections in non-neutropenic ICU-patients].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Fungi; Humans; Intensive | 2003 |
Empirical antifungal therapy in treating febrile neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Fe | 2004 |
[Guidelines for the management of deep mycosis in neutropenic patients].
Topics: Amphotericin B; Aspergillosis; Candidiasis; Echinocandins; Fluconazole; Humans; Lipopeptides; Lipopr | 2004 |
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses | 2005 |
Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Topics: Antifungal Agents; Chi-Square Distribution; Fluconazole; Hematologic Neoplasms; Hematopoietic Stem C | 2005 |
Voriconazole versus amphotericin B in cancer patients with neutropenia.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Fluconazole; Humans; Liposomes; Mycoses; Neoplasms | 2006 |
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.
Topics: Antifungal Agents; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Mycoses; Myelodysplast | 2008 |
[Prophylaxis against mycoses in neutropenic patients].
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Fluconaz | 1994 |
Aspergillus fumigatus pneumonia in neutropenic patients receiving fluconazole for infection due to Candida species: is amphotericin B combined with fluconazole the appropriate answer?
Topics: Amphotericin B; Aspergillosis; Aspergillus fumigatus; Drug Interactions; Drug Therapy, Combination; | 1994 |
Candida tropicalis infections in children with leukemia.
Topics: Abscess; Adolescent; Amphotericin B; Candida; Candidiasis; Cerebrospinal Fluid; Child; Child, Presch | 1993 |
Problems and controversies in the management of hematogenous candidiasis.
Topics: Algorithms; Amphotericin B; Antifungal Agents; Candidiasis; Catheterization, Central Venous; Colony- | 1996 |
Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients.
Topics: Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Flu | 1996 |
Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Miconazole; Myco | 1997 |
[Changes in epidemiology of opportunistic infections due to Candida].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Blood; Bone Marrow Transplantation; Candid | 1995 |
[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation].
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Candidia | 1995 |
Antifungal prophylaxis in neutropenic patients with hematologic malignancies.
Topics: Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Fluconaz | 2000 |
Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.
Topics: Amphotericin B; Antifungal Agents; Confidence Intervals; Fluconazole; Humans; Mycoses; Neoplasms; Ne | 2000 |
Prevention of systemic mycoses in patients who are not neutropenic: should we do it? Can we do it?
Topics: Antifungal Agents; Clinical Trials as Topic; Fluconazole; Fungemia; Humans; Neutropenia; Risk Factor | 2000 |
Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
Topics: Administration, Oral; Antifungal Agents; Antineoplastic Agents; Fluconazole; Humans; Mycoses; Neopla | 2000 |
Therapy for fungal infections in leukemia.
Topics: Amphotericin B; Aspergillosis; Azoles; Candidiasis; Fluconazole; Humans; Immunotherapy; Leukemia; My | 2001 |
[Visceral candidiasis].
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis; Catheterization, Central Venous; Female | 2001 |
[Prevention of fungal infections in children and adolescents with cancer].
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Amphotericin B; Anemia, Aplastic; Antifungal A | 2001 |
Antifungal prophylaxis in hematopoietic stem cell transplant recipients.
Topics: Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole; | 2001 |
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.
Topics: Amphotericin B; Antifungal Agents; Confidence Intervals; Fluconazole; Humans; Mycoses; Neoplasms; Ne | 2002 |
The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia.
Topics: Amphotericin B; Bone Marrow Transplantation; Candidiasis; Disease Susceptibility; Double-Blind Metho | 1992 |
48 trials available for fluconazole and Neutropenia
| Article | Year |
|---|---|
Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Antifungal Agents; Aspergillosis; Caspofungin; Child; Child, Preschool; Early Ter | 2019 |
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Echinocandins; Female; Fluconazole; Hematologic Neoplasm | 2008 |
[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation].
Topics: Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Echinocandins; Female; Fluconazole; | 2009 |
[Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Candidiasis; Catheterization; Double-Blind Method | 2003 |
Comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients," by Garbino et al.
Topics: Antifungal Agents; Candidiasis; Critical Illness; Fluconazole; Humans; Neutropenia; Placebos; Risk F | 2003 |
Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemo | 2004 |
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Double-Blind Method; Echinocandins; Female; Flucon | 2004 |
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Endpoint Determinati | 2006 |
A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Drug Administration Schedu | 2006 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Flucon | 2007 |
Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients.
Topics: Adolescent; Adult; Aged; Amphotericin B; Anemia, Aplastic; Antibodies, Fungal; Antibody Specificity; | 2006 |
Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.
Topics: Adult; Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Bacteremia; Candidi | 1995 |
Prophylactic use of fluconazole in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Female; Fluconazole; Humans; Male; Middle Aged; Mycoses; Neoplasms; Neutrop | 1995 |
Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study.
Topics: Adult; Amphotericin B; Aspergillosis, Allergic Bronchopulmonary; Bone Marrow Transplantation; Female | 1995 |
Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study.
Topics: Adolescent; Adult; Aged; Female; Fluconazole; Humans; Immunocompromised Host; Male; Miconazole; Midd | 1995 |
An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aspergillosis; Aspergillus fumigatus; Candidiasis; Fe | 1995 |
Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients.
Topics: Adolescent; Adult; Aged; Amphotericin B; Candida; Candidiasis; Child; Child, Preschool; Colony Count | 1994 |
The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures.
Topics: Adult; Bone Marrow Transplantation; Candida; Candidiasis; Clotrimazole; Female; Fluconazole; Hematol | 1994 |
[Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; | 1994 |
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.
Topics: Amphotericin B; Candidiasis; Catheters, Indwelling; Female; Fluconazole; Follow-Up Studies; Fungemia | 1994 |
Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome.
Topics: Adult; Candida; Candidiasis, Oral; Esophageal Diseases; Female; Fluconazole; Humans; Male; Middle Ag | 1994 |
Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Clotrimazole; Female; Fluconazole; Humans; Leukemia; | 1994 |
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Amphotericin | 1994 |
The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Candida; Candidiasis; Colony Count, Microbial; Doubl | 1994 |
Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Child; Female; Flu | 1993 |
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Fluconazole; | 1993 |
Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciproflo | 1996 |
[Clinical study on a concomitant therapy with fluconazole and human recombinant granulocyte colony stimulating factor in the treatment of systemic fungal infections with hematological disorders].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; Drug Therapy, Combination; Female; Filgrastim; Fl | 1996 |
Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; A | 1998 |
A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Female; Fever; Fluconazole; Humans; Male; Midd | 1998 |
Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Double-Blind Method; Female; Fluconaz | 1999 |
Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Double-Blind Method; Female; Fluconaz | 1999 |
Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Double-Blind Method; Female; Fluconaz | 1999 |
Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Double-Blind Method; Female; Fluconaz | 1999 |
Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Female; Fluconazole; | 1999 |
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Topics: Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Fluconazole; Hematologic Neoplasms; Hem | 1999 |
A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; | 1999 |
Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Hematologic Neoplasms; Humans; Male; Middle Aged; Myc | 1999 |
Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Chemical and Drug Induc | 2000 |
Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.
Topics: Adolescent; Adult; Aged; Amphotericin B; Bilirubin; Consumer Product Safety; Contraindications; Fema | 2000 |
Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Female; Fluco | 1999 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candidiasis; Female; Flucona | 2000 |
Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.
Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Drug Ther | 2002 |
The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia.
Topics: Amphotericin B; Bone Marrow Transplantation; Candidiasis; Disease Susceptibility; Double-Blind Metho | 1992 |
Prophylactic fluconazole and marrow transplantation.
Topics: Bone Marrow Transplantation; Fluconazole; Humans; Mycoses; Neutropenia; Premedication | 1992 |
[Multicenter study of fluconazole in the treatment of oropharyngeal candidiasis in immunodepressed patients].
Topics: Adult; Candidiasis, Oral; Female; Fluconazole; HIV Infections; Humans; Immunologic Deficiency Syndro | 1990 |
[Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents].
Topics: Administration, Oral; Adolescent; Adult; Aged; Amphotericin B; Antineoplastic Agents; Female; Flucon | 1990 |
Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Bacterial Infections; Candidiasis; Child; Child, P | 1990 |
Management of fungal infection in neutropenic patients with fluconazole.
Topics: Adult; Agranulocytosis; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hematologic Diseases; | 1990 |
121 other studies available for fluconazole and Neutropenia
| Article | Year |
|---|---|
Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy.
Topics: Aged; Antifungal Agents; Echinocandins; Fatal Outcome; Geotrichosis; Geotrichum; Humans; Lipopeptide | 2009 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
Impact of Concomitant Use of Azoles on Bortezomib-related Adverse Drug Reactions Using JADER.
Topics: Azoles; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Fluconazole; Humans; Itraconazo | 2023 |
A case report of catheter-related bloodstream infection due to Trichosporon coremiiforme in a patient with secondary neutropenia to HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Bacteremia; Catheter-R | 2020 |
Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
Topics: Adult; Aged; Candida; Candidemia; Candidiasis; Female; Fever; Fluconazole; Humans; Liver; Male; Midd | 2017 |
Mortality associated with candidemia in non-neutropenic cancer patients is not less compared to a neutropenic cohort of cancer patients.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidemia; Child; Child, Preschool; Cohort Stu | 2017 |
Impact of high MIC of fluconazole on outcomes of Candida glabrata bloodstream infection: a retrospective multicenter cohort study.
Topics: Aged; Antifungal Agents; Candida glabrata; Candidiasis; Cohort Studies; Female; Fluconazole; Humans; | 2018 |
Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Topics: Antifungal Agents; Cost-Benefit Analysis; Decision Support Techniques; Fluconazole; Greece; Health E | 2013 |
EPICO PROJECT. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non- neutropenic critically ill adult patients.
Topics: Antifungal Agents; Candida; Candidiasis, Invasive; Consensus; Critical Illness; Delphi Technique; Ec | 2013 |
Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Topics: Adolescent; Adult; Aged; Amphotericin B; Anti-Infective Agents; Bacteremia; Candidiasis; Child; Chil | 2014 |
Recurrent dermatophytosis (Majocchi granuloma) associated with chemotherapy-induced neutropenia.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Flucon | 2014 |
Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2014 |
Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study.
Topics: Abdominal Cavity; Adult; Aged; Antibiotic Prophylaxis; Antifungal Agents; Candida; Candidemia; Candi | 2014 |
Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Topics: Adolescent; Antifungal Agents; Chemoprevention; Child; Child, Preschool; Cohort Studies; Drug-Relate | 2015 |
Acute isolated appendicitis due to Aspergillus carneus in a neutropenic child with acute myeloid leukemia.
Topics: Acute Disease; Acyclovir; Amphotericin B; Antifungal Agents; Appendicitis; Aspergillosis; Aspergillu | 2016 |
Thalidomide for steroid-dependent chronic disseminated candidiasis after stem cell transplantation: A case report.
Topics: Antifungal Agents; Bone Marrow Transplantation; Candida albicans; Candidiasis; Chronic Disease; Fluc | 2017 |
Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Echinocandins; Female; Fluconazole; Fung | 2017 |
Treatment of aspergillosis.
Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Myelo | 2008 |
The answer is in: fluconazole prophylaxis is not beneficial for intensive care unit patients without neutropenia.
Topics: Antifungal Agents; Candidiasis; Critical Care; Cross Infection; Fluconazole; Fungemia; Humans; Inten | 2008 |
Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Topics: Adult; Aged; Antifungal Agents; Costs and Cost Analysis; Female; Fluconazole; Humans; Itraconazole; | 2008 |
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
Topics: Animals; Antifungal Agents; Brain; Candidiasis; Colony Count, Microbial; Dose-Response Relationship, | 2009 |
Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
Topics: Antifungal Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Fluco | 2008 |
Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; An | 2009 |
Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
Topics: Adult; Aged; Antifungal Agents; Candida glabrata; Candidiasis; Cohort Studies; Critical Care; Critic | 2010 |
Changing trends in the epidemiology of Candida blood stream infections: a matter for concern?
Topics: Antifungal Agents; Candida glabrata; Candidiasis; Critical Care; Cross-Sectional Studies; Drug Resis | 2010 |
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.
Topics: Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, | 2010 |
Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
Topics: Adult; Antifungal Agents; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, D | 2010 |
Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole.
Topics: Administration, Oral; Adolescent; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Aspergil | 2011 |
Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.
Topics: Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Comb | 2011 |
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.
Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Blood; Blood Chemical Analysis; Candida alb | 2012 |
[Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Community-Acquired Infections; Critical Illness; Cro | 2012 |
Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Caspofungin; Disease Models, Animal; Echinocand | 2012 |
Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study.
Topics: Adult; Aged; Antifungal Agents; Blood; Candida; Candidemia; Case-Control Studies; Culture Media; Dru | 2013 |
68-year-old man with neutropenic fever and upper extremity hematoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherap | 2012 |
Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Age | 2003 |
Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; | 2003 |
Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 2003 |
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Topics: Administration, Oral; Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; C | 2003 |
Tuboovarian abscess caused by Candida glabrata in a febrile neutropenic patient.
Topics: Abscess; Adult; Amphotericin B; Antifungal Agents; Antimetabolites, Antineoplastic; Candida glabrata | 2003 |
Alternatives to amphotericin B for Candida rugosa infection.
Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Colony Count, Microbial; Fluconazole; Kidne | 2004 |
Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candidiasis; Female; Fluconazole; Fungemia; Graft vs Hos | 2004 |
How to improve the design of trials of antifungal prophylaxis among neutropenic adults with acute leukemia.
Topics: Acute Disease; Adult; Antifungal Agents; Clinical Trials as Topic; Fluconazole; Humans; Itraconazole | 2004 |
[Prophylaxis of fungal infection in patients with hematologic neoplasms and severe neutropenia after high-dose chemotherapy].
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hema | 2004 |
Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida tropicalis; Candidiasis; Cyclophosphamide; Disea | 2005 |
Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital.
Topics: Antifungal Agents; Candida; Candidiasis; Catheters, Indwelling; Cross Infection; Drug Resistance, Fu | 2005 |
[Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Humans; Immunocompromise | 2005 |
Mucormycoses in patients with hematologic malignancies: an emerging fungal infection.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Communicable Diseases, Emergi | 2005 |
Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antifungal Agents; Aspergillosis; Aspergillus; DNA, Fungal; Female | 2006 |
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Topics: Algorithms; Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Area Under Curve; Candida gla | 2006 |
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis; Cohort Studies; Female; Fever; Fluconazole; | 2006 |
The prophylactic effectiveness of various antifungal agents against the progression of trichosporonosis fungemia to disseminated disease in a neutropenic mouse model.
Topics: Amphotericin B; Animal Structures; Animals; Antibiotic Prophylaxis; Antifungal Agents; Cyclophospham | 2007 |
[Prophylactic administration of fluconazole and itraconazole in febrile neutropenia associated with hematopoietic malignancy].
Topics: Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic | 2006 |
Prophylaxis and aspergillosis--has the principle been proven?
Topics: Antifungal Agents; Aspergillosis; Fluconazole; Graft vs Host Disease; Humans; Itraconazole; Mycoses; | 2007 |
Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients.
Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Endpoint Determination; Female; Fluconazole; Hematopo | 2007 |
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antibiotic Prophylaxis; Antifungal Agent | 2007 |
Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Carrier Proteins; Dose-Response Relations | 2007 |
Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents; Cost-Benefit Analysis; Female; Fl | 2008 |
Elevation of activated platelet-dependent chemokines and soluble cell adhesion molecules in patients with hematologic malignancies and high levels of beta-D-glucan.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; b | 2007 |
The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Catheterization, Central Venous; Cohort Stu | 2008 |
Antifungal susceptibility against yeasts isolated from pediatric oncology patients.
Topics: Adolescent; Adult; Antifungal Agents; Candida; Candidiasis; Catheterization, Central Venous; Child; | 2008 |
A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Mar | 1994 |
Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species.
Topics: Antifungal Agents; Bacteremia; Bronchoalveolar Lavage Fluid; Candida; Candidiasis; Fluconazole; Huma | 1995 |
Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B.
Topics: Amphotericin B; Animals; Candidiasis; Cyclophosphamide; Drug Combinations; Female; Fluconazole; Kidn | 1995 |
SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Fluconazole; Immunosuppression Therapy; Kid | 1995 |
Management of candidemia.
Topics: Adult; Amphotericin B; Candidiasis; Fluconazole; Fungemia; Humans; Neutropenia | 1994 |
Risk factors for hepatosplenic abscesses in patients with acute leukemia receiving empiric azole treatment.
Topics: Abscess; Acute Disease; Adolescent; Adult; Aged; Candidiasis; Female; Fever; Fluconazole; Humans; Le | 1994 |
Notable clinical changes of hepatosplenic abscesses in febrile neutropenic patients receiving empiric antifungal treatment with azoles.
Topics: Abscess; Antifungal Agents; Candidiasis; Fever; Fluconazole; Humans; Leukemia; Liver Abscess; Lympho | 1994 |
Genotypic characterization of sequential Candida albicans isolates from fluconazole-treated neutropenic patients.
Topics: Adult; Base Sequence; Candida albicans; Candidiasis; DNA, Fungal; Electrophoresis, Gel, Pulsed-Field | 1994 |
Prevention of invasive fungal infection during chemotherapy-induced neutropenia in patients with acute leukemia.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Amphoteric | 1994 |
Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice.
Topics: Amphotericin B; Animals; Candidiasis; Fluconazole; Hematopoiesis; Immunosuppression Therapy; Liposom | 1993 |
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.
Topics: Amphotericin B; Bacterial Infections; Bone Marrow Transplantation; Candida; Candidiasis; Fluconazole | 1993 |
Severe candidal infections in neutropenic patients.
Topics: Amphotericin B; Candidiasis; Fluconazole; Humans; Itraconazole; Ketoconazole; Neutropenia | 1993 |
Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Candidiasis; Cytosine; Eto | 1993 |
Fluconazole chemoprophylaxis in neutropenic patients.
Topics: Adult; Candidiasis, Oral; Drug Resistance, Microbial; Female; Fluconazole; Humans; Leukemia, Myeloid | 1993 |
Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species.
Topics: Adolescent; Adult; Aged; Aspergillosis; Aspergillus fumigatus; Candidiasis; Female; Fluconazole; Hum | 1993 |
[Clinical course and risk of fungal infections development in children with treated with chemo- and radiotherapy for solid tumors].
Topics: Antifungal Agents; Candidiasis; Child; Child, Preschool; Female; Fluconazole; Humans; Infant; Male; | 1995 |
Variable antifungal susceptibility of wild-type Candida albicans phenotypes from neutropenic hosts.
Topics: Analysis of Variance; Antifungal Agents; Candida albicans; Candidiasis; Drug Resistance, Microbial; | 1996 |
Early surgical management of invasive gingival aspergillosis in a neutropenic patient with leukemia: a case report.
Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Female; Fluconazole; Flucytosine; Gingival | 1997 |
Detection and identification of fungal pathogens in blood by using molecular probes.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; DNA, Fungal; Fl | 1997 |
Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; D | 1997 |
[Emergency of fluconazole-resistant infections by Candida krusei and Candida glabrata in neutropenic patients].
Topics: Antifungal Agents; Candidiasis; Drug Resistance; Fluconazole; Humans; Neutropenia; Prospective Studi | 1996 |
Can we agree on the treatment of candidiasis?
Topics: Antifungal Agents; Candidiasis; Drug Resistance, Microbial; Drug Therapy, Combination; Fluconazole; | 1997 |
Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis.
Topics: Adult; Antifungal Agents; Candidiasis, Oral; Female; Fluconazole; Humans; Male; Microbial Sensitivit | 1998 |
Clonal expansion of Staphylococcus epidermidis strains causing Hickman catheter-related infections in a hemato-oncologic department.
Topics: Air Microbiology; Antibiotic Prophylaxis; Bacteriological Techniques; Catheterization, Central Venou | 1998 |
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu | 1998 |
Antifungal susceptibility of Aspergillus species isolated from invasive oral infection in neutropenic patients with hematologic malignancies.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; D | 1999 |
Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Disease Models, Animal; Drug Resis | 1999 |
In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.
Topics: Candida; Cryptococcus neoformans; Drug Resistance, Microbial; Fluconazole; Fungemia; Humans; Microbi | 1999 |
Hepatosplenic candidiasis after neutropenic phase of acute leukaemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candidiasi | 1999 |
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Topics: Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; Colony Count, Microbial | 1999 |
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Topics: Amphotericin B; Analysis of Variance; Anidulafungin; Animals; Antifungal Agents; Candida albicans; C | 1999 |
Liposomal amphotericin B for fever and neutropenia.
Topics: Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Candidiasis; Drug Carriers; Fluconazole; | 1999 |
Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution.
Topics: Adrenal Cortex Hormones; Amphotericin B; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal A | 1999 |
Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Meta-Analysis as Topic; Mycoses; Neoplasms; | 1999 |
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antifungal Agents; Bone Marrow Transplantation; Fema | 1999 |
Itraconazole verus fluconazole in neutropenic patients.
Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Itraconazole; Neutropenia | 2000 |
Phenotypic variation and antifungal susceptibility patterns of Candida albicans strains isolated from neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Digestive System; Fluconazole; Flu | 2000 |
Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection; | 2000 |
Candida krusei fungemia. An escalating serious infection in immunocompromised patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Agents | 2000 |
Management of persistent fever in the neutropenic patient.
Topics: Amphotericin B; Antifungal Agents; Fever; Fluconazole; Humans; Mycoses; Neutropenia | 2000 |
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Azoles; Bone Marrow Transplantation; Candida; Candidiasis; Drug R | 2001 |
Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Candida; Candidiasis; D | 2001 |
Empirical antifungal therapy for persistent fever in patients with neutropenia.
Topics: Amphotericin B; Antifungal Agents; Aspergillus; Deoxycholic Acid; Drug Combinations; Fever; Fluconaz | 2001 |
Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321).
Topics: Antifungal Agents; Aspergillosis; Fever of Unknown Origin; Fluconazole; Humans; Neutropenia | 2001 |
Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antibiotic Prophylaxis; | 2000 |
[Visceral mycotic infections. In clinical practice].
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Cryptococcosis; Fluconazole; Flucytosine; Histoplasm | 2001 |
[Retrospective analysis of fluconazole efficacy in Candida-colonized, non-neutropenic, surgical patients in long-term intensive care].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; APACHE; Candidiasis; Critical Care; F | 2001 |
Scedosporium endophthalmitis: two fatal disseminated cases of Scedosporium infection presenting with endophthalmitis.
Topics: Acute Disease; Adult; Amphotericin B; Antifungal Agents; Endophthalmitis; Eye Infections, Fungal; Fa | 2001 |
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Topics: Adolescent; Adult; Antifungal Agents; Bacteremia; Bone Marrow Transplantation; Candida; Candidiasis; | 2001 |
Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia.
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis, Oral; Capsules; | 2002 |
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
Topics: Amphotericin B; Antifungal Agents; APACHE; Bone Marrow Transplantation; Candida albicans; Candidiasi | 2002 |
Risk factors for breakthrough candidemia.
Topics: Amphotericin B; Anti-Bacterial Agents; Candidiasis; Fluconazole; Fungemia; Humans; Multivariate Anal | 2002 |
Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice.
Topics: Animals; Candidiasis; Female; Fluconazole; Interleukin-1; Kidney; Leukocyte Count; Liver; Mice; Neut | 1992 |
The comparative efficacy of cilofungin, fluconazole and amphotericin B in disseminated Candida tropicalis infection in neutropenic mice.
Topics: Amphotericin B; Animals; Candida; Candidiasis; Echinocandins; Female; Fluconazole; Injections, Intra | 1992 |
Prevention of infection during neutropenia.
Topics: Ciprofloxacin; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female; Fluconazole; Huma | 1992 |
Fluconazole or amphotericin for candidosis in neutropenic patients.
Topics: Adult; Aged; Amphotericin B; Candidiasis; Fluconazole; Humans; In Vitro Techniques; Neutropenia | 1991 |
Fluconazole or amphotericin for candidaemia in non-neutropenic patients?
Topics: Adult; Amphotericin B; Candidiasis; Fluconazole; Humans; Male; Neutropenia | 1991 |
Fluconazole and Candida krusei infections.
Topics: Acute Disease; Candidiasis; Drug Resistance, Microbial; Female; Fluconazole; Fungemia; Humans; Leuke | 1991 |
Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Candidiasis, Oral; Drug Evaluation; Esophagitis; | 1991 |
Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis.
Topics: Adult; Candidiasis; Enterocolitis; Fluconazole; Humans; Leukemia, Monocytic, Acute; Male; Neutropeni | 1991 |
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Fluconaz | 1989 |